Ibogaine and Parkinson's Disease: What the Research Shows

Interest in ibogaine for Parkinson's disease comes from one idea: in animal studies, ibogaine increases GDNF, a growth factor that protects dopamine-producing neurons. In 2026, the first case report using validated scales described a 52-year-old woman whose motor symptoms, fatigue, mood and quality of life improved after 80 days of low daily doses of ibogaine. It is a single case, not proof, and it used a very different approach from the single-dose treatment used for addiction.

Key takeaways

• Parkinson's disease is caused by the loss of dopamine-producing neurons, and current medicines treat symptoms but do not stop the disease.
• Ibogaine increases GDNF in animal studies, and GDNF protects dopamine neurons, which is the main reason for interest.
• The only published human case (Journal of Psychedelic Studies, 2026) used low doses of up to 75 mg a day for 80 days.
• The patient improved in motor symptoms, quality of life, fatigue and depression; her sleep got worse; no adverse events were recorded.
• There are no clinical trials. Ibogaine is not an approved or proven treatment for Parkinson's.

Why researchers are interested

Parkinson's disease develops as neurons that produce dopamine gradually die in a region of the brain called the substantia nigra. Levodopa and other medicines replace or mimic dopamine and improve symptoms, but they lose effectiveness over time and do not slow the disease.

GDNF (glial cell line-derived neurotrophic factor) is a protein that supports and protects dopamine neurons. In animal research, ibogaine increased GDNF in brain areas linked to reward and movement. Attempts to deliver GDNF directly into the brain through surgery produced mixed results in clinical trials, so researchers are looking for drugs that can raise GDNF naturally. Ibogaine may also affect the dopamine transporter, which regulates dopamine signaling.

The 2026 case report

Published in the Journal of Psychedelic Studies by Erny, Cano Montenegro, Barth and Noller, the report describes a 52-year-old woman with Parkinson's whose response to conventional therapy was declining. She received gradually increasing daily doses of ibogaine hydrochloride, up to 75 mg a day, for 80 days. Researchers measured her symptoms before and after with standard Parkinson's scales.

She reported fewer episodes of freezing of gait, better mobility, more energy, better mood and more optimism. No adverse events were recorded. The authors called the findings preliminary and said larger controlled trials are needed.

What we still do not know

• One person is not evidence. A single case can be affected by placebo effects, natural fluctuations and changes in other treatments.
• The dose was very different. This case used low daily doses over months, not the single large dose used in addiction treatment. The effects and risks of a single large dose in people with Parkinson's are unknown.
• Long-term effects on disease progression have not been studied.

Specific risks for people with Parkinson's

• Falls: ibogaine commonly causes ataxia (loss of coordination) for many hours. Combined with Parkinson's balance problems, the fall risk is high.
• Blood pressure: Parkinson's often causes orthostatic hypotension (drops in blood pressure when standing), and ibogaine also affects heart rate and blood pressure.
• Medication interactions: Parkinson's medications, and drugs often used alongside them for nausea, sleep or mood, can interact with ibogaine or affect the heart's QT interval.
• Age-related heart conditions: people with Parkinson's are often older and more likely to have heart disease, which must be ruled out.

Read more in ibogaine side effects and heart safety and noribogaine and neuroplasticity.

Our position

Ibogaine Center Cancún's program is designed for addiction, trauma and related conditions, not Parkinson's disease. If you have Parkinson's and are interested in ibogaine, we recommend talking to your neurologist and following clinical trials. If you have Parkinson's and are seeking treatment for another condition, such as an addiction, our medical team can evaluate whether it would be safe.

Frequently asked questions

Can ibogaine cure Parkinson's disease?

No. There is no evidence that ibogaine cures or stops Parkinson's. One case report described symptom improvements with low daily doses, but controlled trials have not been done.

What dose was used in the Parkinson's case?

Gradually increasing daily doses of ibogaine hydrochloride, up to 75 mg a day, for 80 days. This is very different from the single large dose used for addiction. Do not try to replicate it without medical supervision.

What is GDNF?

A protein that supports and protects dopamine-producing neurons. Animal studies show ibogaine increases it, which is the main theory behind its possible use in Parkinson's.

Are there clinical trials of ibogaine for Parkinson's?

Not that we know of. Arizona's 2025 research funding is aimed at ibogaine for neurological conditions, which could lead to future studies.

Can I stop my Parkinson's medication to try ibogaine?

No. Stopping Parkinson's medication suddenly can be dangerous. Any change must be made with your neurologist.

References

• Erny, T., Cano Montenegro, E. Y., Barth, J., Noller, G. "Ibogaine for the treatment of Parkinson's disease: a case report." Journal of Psychedelic Studies, 2026.
• He, D.-Y. et al. "Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption." Journal of Neuroscience, 2005. PubMed

Have Parkinson's and another condition you want to treat? Our medical team will review your case confidentially and tell you honestly what is safe. Request your evaluation.